Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine

−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus... | March 30, 2023

Related Keywords

United States ,Japan ,Canada ,Australia ,Switzerland ,Australian ,Simon Travis ,John Cunningham ,Fachinformation Entyvio ,Marcelo Freire ,Exchange Commission ,Global Medical Affairs ,European Union ,Kennedy Institute ,University Of Oxford ,Takeda Pharmaceutical Company Limited ,New England Journal ,Professor Simon Travis ,Translational Gastroenterology Unit ,Vice President ,Therapeutic Area Head ,Safety Information ,Special Precautions ,Site Reactions ,Product Characteristics ,Prescribing Information ,Medication Guide ,Rare Genetics ,Plasma Derived Therapies ,Annual Report ,Inflamm Bowel ,Chronic Pouchitis ,Patient Medication ,Receives Approval ,Market Entyvio Subcutaneous Injection ,Maintenance Treatment ,Severe Ulcerative ,Pharmacol Exp ,Vedolizumab Patient Exposure ,Takeda Pharmaceutical Company Limited Stock Exchange ,News ,Information ,Press Release ,Hase , ,Earnest ,Study ,Pet ,Its ,Primary ,Efficacy ,Ndpoint ,F ,Remission ,Hronic ,Dr ,Recurrent ,Pouchitis ,It ,Eek ,Ith ,Participants ,Receiving ,Vedolizumab ,Chieving ,Emission 4502 Jp3463000004 ,